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Abstract
Background: Plasminogen activators are known to play a key role in the remodeling of bone
matrix which occurs during tumor progression, bone metastasis and bone growth. Dysfunctional
remodeling of bone matrix gives rise to the osteoblastic and osteolytic lesions seen in association
with metastatic cancers. The molecular mechanisms responsible for the development of these
lesions are not well understood. Studies were undertaken to address the role of the plasminogen
activator system in the regulation of fibronectin matrix assembly in the osteoblast-like cell line, MG-
63.
Results: Treatment of MG-63 cells with P25, a peptide ligand for uPAR, resulted in an increase in
assembly of fibronectin matrix which was associated with an increase in the number of activated
β1 integrins on the cell surface. Overexpression of uPAR in MG-63 cells increased the effect of P25
on fibronectin matrix assembly and β1 integrin activation. P25 had no effect on uPAR null
fibroblasts, confirming a role for uPAR in this process. The addition of plasminogen activator
inhibitor Type I (PAI-1) to cells increased the P25-induced fibronectin polymerization, as well as
the number of activated integrins. This positive regulation of PAI-1 on fibronectin assembly was
independent of PAI-1's anti-proteinase activity, but acted through PAI-1 binding to the
somatomedin B domain of vitronectin.
Conclusion: These results indicate that vitronectin modulates fibronectin matrix assembly in
osteosarcoma cells through a novel mechanism involving cross-talk through the plasminogen
activator system.
Introduction
Bone metastasis is a significant complication in tumor
progression and a contributing cause of patient mortality.
Contributing factors to such skeletal "homing" include
the ability of the tumor to stimulate remodeling of the
bone matrix thereby providing a niche supportive of its
survival and growth [reviewed in [1]]. Fibronectin is a
component of the bone matrix and is necessary for oste-
oblast differentiation and survival [2-4]. Recent in vivo
studies have demonstrated a role for specific matrix-
remodeling proteases (e.g. plasminogen activators) in the
maintenance of bone mass and tissue composition [5],
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suggesting both fibronectin and the plasminogen activa-
tor system are important regulators of bone formation.
Formation of fibronectin matrix requires a cell-driven
mechanical stretching of fibronectin, which is progres-
sively incorporated into a dense detergent-insoluble fibril-
lar network via interactions with other cell-associated
fibronectin dimers [reviewed in [6]]. The assembly of the
fibronectin matrix requires activated α5β1 integrins [7,8].
Regulation of α5β1  integrin activation is thought to
involve changes in integrin conformation which affect its
affinity for fibronectin [9]. Downstream of fibronectin
ligation, additional integrin dependent steps in the regu-
lation of matrix assembly may occur in response to
changes in key intracellular signaling pathways [10] or
through the formation of complexes with either cytoskel-
etal proteins [11] or cell surface molecules including the
glycosylphosphatidylinositol (GPI)-anchored urokinase-
type plasminogen activator receptor (uPAR) [12-14]. High
levels of uPAR expression have been shown to lead to for-
mation of uPAR/β1 complexes which modulate integrin
signaling and adhesive function [15,16]. uPAR effects on
α5β1 function are complex and may result in either gain
or loss of function depending on cellular context [15,17].
Several peptides have been identified which can modulate
the functional association of integrins with uPAR [12,18].
Among them, peptide P25, isolated from a peptide library
screening, is able to directly bind to uPAR and modulate
integrin activity [12,15,19,20].
uPAR binds directly to the somatomedin B (SMB) domain
of vitronectin and supports adhesion of a number of dif-
ferent cell types [21,22]. Plasminogen activator inhibitor
Type I (PAI-1), the major physiological regulator of uPA
activity, binds in close proximity to the uPAR recognition
site within the SMB domain and can competitively inhibit
or displace uPAR-vitronectin interactions [22,23]. The
PAI-1 binding site on vitronectin is close to the only RGD
motif in vitronectin [21] and the binding of PAI-1 to vit-
ronectin can sterically inhibit integrin dependent adhe-
sion to this motif [22,24]. Thus, PAI-1 can modulate the
association of both uPAR- and/or integrins with vitronec-
tin.
Treatment of human dermal fibroblasts with the uPAR lig-
and, P25, results in a marked increase in the polymeriza-
tion of the fibronectin matrix and in the level of β1
integrin activation [13,14]. In the present study, we now
show that overexpression of uPAR in MG-63 cells
increases the effects of P25 on both fibronectin matrix
assembly as well as integrin activation. In addition, P25
has no effect on matrix assembly in uPAR null cells. Our
results also show that uPAR and PAI-1 synergistically reg-
ulate the amount of fibronectin deposition into the
matrix. The positive regulation of PAI-1 on fibronectin
assembly requires the presence of vitronectin suggesting
uPAR regulation of fibronectin matrix formation in MG-63  cells Figure 1
uPAR regulation of fibronectin matrix formation in 
MG-63 cells. A – MG-63 cells were incubated with 125I-
fibronectin for 6 hours in the presence of the indicated con-
centrations of P25 in DMEM containing 0.02% BSA. Cell lay-
ers were extracted with 1% DOC, and 125I-fibronectin that 
was incorporated into the detergent-insoluble matrix 
fibronectin was recovered by centrifugation and measured by 
gamma scintillation. Control wells contained no added pep-
tide. B – MG-63 cells were preincubated for 2 h with 20 µg/
ml of normal mouse IgG or clone 6S6 antibody, a function-
blocking monoclonal antibody against the β1 integrin, and 
then treated with 50 µM P25 or S25 in the presence of 125I-
fibronectin (FN) for 6 hours. Cell layers were extracted in 
1% DOC, and 125I-Fn that was incorporated into the deter-
gent-insoluble matrix was recovered by centrifugation and 
measured by gamma scintillation.Cancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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Increase in the formation of matrix and ECM contacts in P25-treated MG-63 cells Figure 2
Increase in the formation of matrix and ECM contacts in P25-treated MG-63 cells. A – MG-63 cell monolayers 
were incubated for 16 hours in DMEM containing 2 µg/ml AlexaFluor488 derivatized plasma fibronectin (green) in the presence 
of 50 µM S25 (a, b) or P25 (d, e). Cells were subsequently fixed, permeabilized and endogenous fibronectin was visualized by 
indirect immunofluorescence using the IST-9 antibody specific for cell-derived fibronectin (red). Panels c and f show merged 
images indicating colocalization of P25-dependent fibronectin polymerization with endogenous fibronectin matrix. B – Cells in 
suspension were allowed to attach for 6 hours on fibronectin-coated coverslips in DMEM containing soluble AlexaFluor488-
fibronectin (20 µg/ml, green), in the presence of 50 µM S25 (a, b) or P25 (d, e). Cells were fixed, permeabilized, and activated 
β1 integrin was visualized by indirect immunofluorescence using the 9EG7 antibody (red). Panels c and f show merged images 
indicating colocalization of activated integrins with fibronectin fibers.Cancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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that PAI-1 and vitronectin work cooperatively to regulate
the amount of fibronectin matrix in MG-63 cells.
Results
The uPAR ligand P25 enhances the β1 integrin-dependent 
formation of fibronectin matrix in MG-63 cells
We have previously shown that uPAR can regulate
fibronectin matrix assembly in human fibroblast cells
[14]. To determine whether a similar regulation existed in
bone cells, human osteosarcoma (MG-63) cell layers were
incubated with the uPAR ligand P25. Matrix assembly was
assessed by monitoring the incorporation of 125I-fibronec-
tin into detergent insoluble matrix. Incubation of osteosa-
rcoma cells with P25 resulted in a dose-dependent
increase in the assembly of 125I-fibronectin into the deter-
gent-insoluble extracellular matrix (Figure 1A). Concen-
trations of P25 ranging from 10 to 200 µM produced a 3–
35-fold increase in the level of fibronectin present in the
detergent-insoluble matrix. Effects of P25 on matrix
assembly were saturable reaching a maximum increase at
doses between 75–100 µM. Experiments done in the pres-
ence of the control scrambled peptide, S25, were similar
to untreated cell layers and indicated that S25 had no
effect on matrix assembly (data not shown). The P25
enhancement of matrix assembly was largely dependent
on the β1 integrin, as a function-blocking monoclonal
antibody against the β1 integrin, clone 6S6 [34,35], atten-
uated the effects of P25 on matrix assembly by 65% (Fig-
ure 1B).
P25 enhances fibronectin deposition into preformed 
matrix and accelerates the formation of extracellular 
(ECM) contacts
The localization of exogenous plasma fibronectin within
the cell layer following P25 treatment was determined
using fluorescence microscopy. Cell monolayers were
incubated for 16 hours with 2 µg/ml plasma fibronectin
derivatized with AlexaFluor488 in the presence of 50 µM of
either P25 or S25. The deposition of exogenous
AlexaFluor488 derivatized fibronectin into the extracellular
matrix was greatly enhanced in the presence of P25 (Fig-
ure 2A). Endogenous fibronectin was visualized using the
IST-9 monoclonal antibody, which recognizes the alterna-
tively spliced type III repeat, EDA, not found in plasma
fibronectin [36]. The merged images indicate extensive co-
localization of exogenous fibronectin with the endog-
enous fibronectin matrix, indicating that the P25 stimu-
lates the assembly of exogenous fibronectin into
preformed matrix.
The effect of P25 on the initial stages of matrix assembly
was also examined. The early stages of fibronectin matrix
assembly have been shown to occur in regions of cell-
extracellular matrix (ECM) contact [37,38]. To examine
the role of uPAR in the formation of ECM contacts, cells
in suspension were allowed to attach for 6 hours on
fibronectin-coated coverslips in medium containing solu-
ble AlexaFluor488-fibronectin in the presence of 50 µM
S25 or P25 (Figure 2B). Areas of cell-ECM contact were
visualized by staining for active β1 integrin using the anti-
body 9EG7 [32]. Control cells treated with S25 showed
clustered active β1 integrins which colocalized with fine
fibronectin fibrils (Figure 2B, a-c). Active integrins and
fibronectin fibrils were primarily seen at the periphery of
the cell. Incubation of MG-63 cells with P25 induced a
clear enhancement in the number of ECM contacts with
more clusters of active integrins seen in the central and
perinuclear regions of the cell. These results indicate that
P25 stimulates the formation of ECM contacts in MG-63
cells.
uPAR levels modulate the effects of P25 on the assembly of 
fibronectin matrix
To determine whether the effect of P25 on matrix assem-
bly was specific for uPAR, experiments were designed to
address whether the P25-mediated increase in fibronectin
matrix assembly was sensitive to uPAR levels. MG-63 cells
were stably transfected with a plasmid containing the
cDNA for human uPAR. Parental MG-63 cells express
uPAR but at reduced levels compared with either human
fibrosarcoma (HT-1080) or human fibroblast cells (data
not shown). MG-63 cells transfected with uPAR exhibited
a large increase in the levels of uPAR as compared with
cells transfected with vector (V) alone (Figure 3A). uPAR
was not visible in the vector alone transfectants due to the
exposure time of the blot; however, these cells exhibited
the same level of endogenous uPAR as the parental MG-
63 cells (data not shown). uPAR overexpressing cell lines
were compared with cell lines transfected with vector
alone for their ability to polymerize fibronectin (Figure
3B). When compared with cells transfected with only vec-
tor in the presence of control peptide S25, cell lines over-
expressing uPAR exhibited no change in the assembly of
fibronectin matrix, indicating that overexpression of
uPAR did not affect basal levels of matrix assembly. When
stimulated with the uPAR ligand, P25, cells expressing
only vector exhibited a 6-fold increase in the level of
matrix assembly. This stimulation by P25 was increased to
nearly 12-fold in cells overexpressing uPAR.
To confirm a role for uPAR in P25-mediated fibronectin
matrix assembly, fibroblasts derived from uPAR null mice
were tested for their ability to assemble matrix in response
to P25. As shown in Figure 3C, incubation of wild-type
mouse embryo fibroblasts (MEF) with P25 resulted in a
10-fold increase in matrix assembly. In contrast, there was
no effect of P25 on matrix assembly by uPAR-/- cells.
Reexpression of uPAR in uPAR -/- cells restored the ability
of the cells to increase matrix assembly in response to P25.
There was no difference in the incorporation of fibronec-Cancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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tin into matrix between the uPAR +/+ and uPAR -/- cells in
the absence of P25. The data indicate that uPAR is
required for the effects of P25 on matrix assembly and that
the levels of uPAR on the cell surface can modulate the cel-
lular response to P25. The data further indicate that basal
levels of matrix assembly are not under uPAR regulation.
P25 increases the level of active β1 integrins on uPAR 
overexpressing cells
To determine whether the enhanced effect of P25 on MG-
63 cells overexpressing uPAR was associated with changes
in integrin activation, the effect of P25 on β1 integrin acti-
vation was evaluated in MG-63 cells which overexpress
uPAR. Activated integrins were detected using the mono-
clonal antibody HUTS-4, which recognizes only the active
conformation of the β1 integrin. Overexpression of uPAR
in untreated cells or control peptide, S25, treated cells had
no effect on basal levels of HUTS-4 binding (Figure 4A),
suggesting that overexpression of uPAR alone does not
effect integrin activation or changes in matrix assembly in
MG-63 cells. The addition of P25 to vector-transfected
cells resulted in a 8–9 fold increase in the level of HUTS-4
binding as compared with S25-treated cells. In cell lines
overexpressing uPAR, the addition of P25 led to a nearly
30-fold increase in HUTS-4 binding. This suggests that the
over-expression of uPAR leads to a greater β1 integrin acti-
vation after P25 treatment, as compared to vector-trans-
fected cells. To determine whether the addition of P25 or
the overexpression of uPAR affected the total number of
β1 integrins on the cell surface, cells overexpressing uPAR
or cells containing vector alone were incubated with P25,
and levels of β1 were assessed using P5D2, an antibody
that recognizes active and inactive forms of β1. Neither
P25 nor uPAR overexpression modified the surface
expression of β1 integrin (Figure 4B). These data indicate
that addition of P25 to MG-63 cells results in an increase
in the activation state of the β1 integrin and that uPAR lev-
els modulate the P25 response in these cells. Since the β1
integrin blocking antibody 6S6 reduced the P25-induced
fibronectin matrix assembly (Figure 1B), our data also
suggest that the effects of P25 on matrix assembly result
from an increase in uPAR-dependent β1 integrin activa-
tion.
Effect of uPA and PAI-1 on integrin activation and 
fibronectin matrix assembly
To determine whether other components of the plas-
minogen-activator system could affect the assembly of the
fibronectin matrix, cells were incubated with increasing
concentrations of urokinase-type plasminogen activator
(uPA) or PAI-1. Incubation of MG-63 cells with increasing
doses of active uPA had no effect on the assembly of
fibronectin matrix in S25- and P25-treated MG-63 cells
(data not shown). PAI-1, however, was able to modulate
matrix assembly. Treatment of MG-63 cells with increas-
Effect of uPAR expression levels on P25-induced fibronectin  matrix assembly Figure 3
Effect of uPAR expression levels on P25-induced 
fibronectin matrix assembly. A – Lysates were prepared 
from vector (V) or uPAR transfected (uPAR) stable lines of 
MG-63 cells. uPAR levels were analyzed by Western blotting 
with anti-uPAR antibody. The membrane was stripped and 
reprobed with anti β-actin antibody as a loading control. B – 
Vector and uPAR transfected cell lines were cultured over-
night and then stimulated with 50 µM S25 or P25 for 6 h in 
the presence of 125I-fibronectin. Cell layers were extracted in 
1% DOC, and 125I-fibronectin that was incorporated into the 
detergent-insoluble matrix fibronectin was recovered by cen-
trifugation and measured by gamma scintillation. C – uPAR-/- 
MEF were transiently transfected with the cDNA for human 
uPAR. 24 hours after transfection, MEFs were washed and 
monolayers were stimulated with 50 µM S25 or P25 for 6 
hours in the presence of 125I-fibronectin. Cell layers were 
extracted in 1% DOC, and 125I-fibronectin that was incorpo-
rated into detergent-insoluble matrix was recovered by cen-
trifugation and measured by gamma scintillation. Control 
cells received no added peptide.Cancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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ing doses of PAI-1 had no effect on fibronectin binding to
the cell layer in the presence of the control peptide S25
(Figure 5A). In contrast, PAI-1 in the presence of the P25
peptide elicited a dose-dependent increase in fibronectin
deposition. Maximum levels of fibronectin deposition
were seen between 1–5 µg/ml PAI-1 as increasing
amounts of PAI-1 resulted in no further stimulation (data
not shown). The PAI-1 mediated increase in fibronectin
binding to the cell layer was accompanied by an increase
in β1 integrin activation (Figure 5B). PAI-1 had no effect
on the level of total β1 integrin (Figure 5C). These data
indicate that under conditions of uPAR stimulation, PAI-
1 positively regulates both β1 integrin activation and
matrix assembly.
PAI-1 enhances P25-stimulated fibronectin polymerization 
through a vitronectin dependent mechanism
In addition to binding to uPA/uPAR complexes, PAI-1
also binds directly to matrix vitronectin. To determine
whether the effects of PAI-1 on matrix assembly required
vitronectin, MG-63 cells were seeded overnight onto wells
coated with either fibronectin or vitronectin. PAI-1 had no
effect on matrix assembly when cells were adherent to
fibronectin, but stimulated the amount of fibronectin
incorporated into the matrix when cells were plated onto
vitronectin-coated substrates (Figure 6A). Several studies
have shown that the PAI-1 binding site in vitronectin is
within the amino terminal 40-amino acid somatomedin B
(SMB) domain [21,23,39]. To evaluate whether the bind-
ing of PAI-1 to vitronectin was required for the effect of
PAI-1 on matrix formation, cells were seeded overnight on
wells coated with either vitronectin or the vitronectin frag-
ment 40–459, which lacks the PAI-1 binding site. This vit-
ronectin fragment contains a deletion of the SMB domain
(aa 1–39), but retains the integrin binding site and medi-
ates attachment and spreading of cells. The stimulatory
effect of PAI-1 on the P25 induced formation of fibronec-
tin matrix was not seen on cells plated onto wells coated
with the vitronectin fragment 40–459 (Figure 6B). These
results suggest that the regulation of fibronectin matrix
polymerization by PAI-1 requires the binding of PAI-1 to
vitronectin.
In addition to binding to vitronectin, PAI-1 also binds to
uPA and inhibits its catalytic activity. To determine
whether PAI-1's vitronectin or uPA binding sites were
required for PAI-1's effect on matrix assembly, mutant
forms of PAI-1 were compared for their ability to stimu-
late matrix assembly on cells adherent to vitronectin (Fig-
ure 7A). PAI-1R, a mutant form which does not bind to
uPA but does bind to vitronectin [25] stimulated fibronec-
tin polymerization to the same extent as wild-type PAI-1,
indicating that the effects of PAI-1 on matrix assembly do
not require the association of PAI-1 with uPA. In contrast,
PAI-1 (Q123K) which does not bind to vitronectin but
does bind uPA [40], failed to enhance the P25-dependent
matrix assembly. Similarly, no stimulatory effect on
matrix formation was observed when MG-63 cells were
Overexpression of uPAR increases P25-induced β1 integrin  activation Figure 4
Overexpression of uPAR increases P25-induced β1 
integrin activation. Stable MG-63 cell lines transfected 
with either vector alone or vector containing the cDNA for 
human uPAR were grown to confluency in 24-well plates. 
The following day, cells were incubated for 2 hours in DMEM 
containing 50 µM P25 or S25. Supernatant was removed and 
cells were then incubated for 1 hour with 100 ng/ml of a 
monoclonal antibody (HUTS-4) which recognized either the 
active form of the β1 integrin (A) or another monoclonal 
antibody which recognized total β1 integrin (B). Cell layers 
were washed, fixed in paraformaldehyde, and incubated with 
a peroxidase conjugated secondary antibody. Bound antibody 
was detected by incubating cells with substrate, and color 
development was measured at A490 in a plate reader.Cancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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treated with the preformed complex uPA-PAI, which is
not able to bind vitronectin [41,42] (Figure 7B). Collec-
tively, these results indicate that the stimulatory effect of
PAI-1 on fibronectin matrix assembly requires PAI-1 bind-
ing to vitronectin but not uPA.
Discussion
We have identified a role for the plasminogen activator
system and vitronectin in the regulation of fibronectin
matrix assembly in the human osteoblast-like cell line,
MG-63. uPAR acts in concert with PAI-1 to stimulate
fibronectin matrix deposition by increasing the level of
α5β1 integrin activation. In addition, the effects of P25 on
assembly of fibronectin matrix were modulated by the
level of uPAR expression. Cells overexpressing uPAR were
more sensitive to the effects of P25, while uPAR -/- cells
were unable to respond to P25. Reexpression of uPAR in
uPAR -/- cells restored the P25 response confirming that
the effect of P25 on matrix assembly was specific to uPAR.
This finding is in agreement with earlier studies which
have shown that matrix assembly can be regulated
through uPAR [14]. Other studies have shown that in
some tumor cells, high levels of uPAR expression corre-
lated with an increase in the formation of fibronectin
matrix [43]. In our studies, neither increasing the levels of
uPAR in MG-63 nor restoring uPAR to uPAR -/- cells
increased the incorporation of fibronectin into matrix,
unless the cells were stimulated with P25. This suggests
that in MG-63 cells as well as MEFs, basal levels of matrix
assembly are not under uPAR regulation.
P25 induced a several fold increase in the rate of assembly
of exogenous fibronectin into previously established
matrix. Furthermore, when suspended MG-63 cells were
allowed to adhere to fibronectin, P25 increased the
number and size of ECM contacts as well as the level of
activated β1 integrin present in the ECM contacts. Several
earlier studies have shown that polymerization of
fibronectin matrix originates in cell adhesion sites,
requires the presence of activated β1 integrins and can be
modulated by changes in the level of integrin activation
[7,8,37]. Taken together, these results suggest that in MG-
63 cells ligation of uPAR with P25 results in an increase in
both assembly of exogenous fibronectin into preformed
matrix as well as an increase in the initiation of matrix
assembly sites in newly adherent cells. The effects of P25
on matrix assembly were significantly attenuated in the
presence of a blocking antibody to the β1 integrin, sug-
gesting that the P25 induced increase in matrix assembly
was the direct result of the increase in β1 integrin activa-
tion. This observation is in agreement with previous stud-
ies showing that addition of P25 to cells stimulates the
adhesion function of the α5β1 integrin [15,19]. P25
induced matrix assembly was not completely inhibited by
β1 blocking antibodies suggesting that P25 may stimulate
alternate mechanisms of matrix assembly by promoting
the binding of fibronectin to β3 integrins or to unfolded
matrix fibronectin molecules [44,45].
P25 directly interacts with uPAR and shares some
sequence homology with integrin α subunits [12,15,18].
uPAR has been found to both physically and functionally
associate with several different integrin receptors [46,47].
The direct interaction of P25 with uPAR may well affect
uPAR modulation of integrin function [12,48], however
its mechanism of action remains unclear. Dimerization/
oligomerization of uPAR can affect its subcellular localiza-
tion by driving uPAR into lipid rafts [49]. As lipid rafts are
sites of integrin activation [50], P25-mediated changes in
uPAR localization to lipid rafts could promote the activa-
tion of raft-associated integrins.
PAI-1 may play a role in the regulation of the uPAR-
dependent formation of fibronectin matrix. Up-regula-
tion of matrix assembly by PAI-1 was observed under con-
ditions of uPAR stimulation and was accompanied by an
increase in the activation of the β1 integrin. The PAI-1
mediated increase in integrin activation and fibronectin
matrix assembly required the binding of PAI-1 to vitronec-
tin, but was independent of the binding of PAI-1 to uPA.
The mechanism whereby PAI-1 binding to vitronectin
might further increase β1 integrin activation is not
known. Binding of PAI-1 to the SMB domain of vitronec-
tin blocks the binding of both uPAR and vitronectin-
integrin receptors to vitronectin [22,24], suggesting that
loss of either uPAR-vitronectin and/or integrin-vitronec-
tin binding may be part of the mechanism by which PAI-
1 modulates fibronectin matrix formation. Vitronectin
negatively regulates matrix assembly [51-53] therefore,
"disengagement" of either uPAR or vitronectin integrins
from vitronectin by PAI-1 may release the inhibitory effect
of vitronectin on matrix assembly. Alternatively, PAI-1
mediated release of uPAR from vitronectin may free uPAR
to form complexes with other cell surface molecules.
Complexes of uPAR with α5β1 integrins would then pro-
mote further integrin activation [13,17]. Alternatively,
uPAR may complex with other receptors including G-pro-
tein linked receptors or growth factor receptors which
affect signaling molecules important in integrin function
[12,48,54]. A recent study has reported that PAI-1 initiates
cellular detachment from both vitronectin and fibronec-
tin substrates, suggesting a PAI-dependent negative effect
on the adhesive function of both β3 and β1 integrins [55].
In these studies, the effects of PAI-1 on cell adhesion were
independent of vitronectin, but required the binding of
PAI-1 to uPA. The reason for the discrepancy between the
two studies may reflect the choice of cell type. Our exper-
iments were performed on MG-63 cells which assemble a
robust extracellular matrix, while the earlier studies usedCancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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HT-1080 fibrosarcoma cells which do not assemble an
extracellular matrix.
Bone destruction during metastasis is marked by loss of
collagenous matrix [56]. Deposition and organization of
collagenous matrix is intrinsically linked to the assembly
of the fibronectin matrix which serves as the core scaffold-
ing on which the collagenous matrix is built [57,58]. Our
results in MG-63 cells highlight a new mechanism by
which PAI-1 and uPAR work synergistically to increase the
formation of fibronectin matrix and suggests that thera-
peutic antagonists of this pathway may attenuate the inap-
propriate deposition of excess matrix often seen in
osteoblastic lesions. Alternatively, modalities directed at
increasing levels of fibronectin in bone matrix (i.e., uPAR
ligands) might prove useful in the control of osteolytic
metastasis, particularly under conditions where inhibitors
of bone resorption are not effective [59]. Increased levels
of fibronectin, moreover, would be expected to promote
the differentiation and survival of osteoblasts, which are
often rendered inactive in sites of bone metastasis. Future
studies are needed to determine whether the vitronectin/
plasminogen activator system are therapeutic targets for
the control of bone metastasis.
Conclusion
Our data show that uPAR and PAI-1 can positively regu-
late the activation state of the β1 integrin and increase the
rate of fibronectin polymerization in human osteosar-
coma cells. The effects of PAI-1 on matrix assembly are
independent of uPA but require the binding of PAI-1 to
vitronectin. These results highlight a new role for vitronec-
tin and the plasminogen activation system in the regula-
tion of bone matrix remodeling.
Methods
Reagents and antibodies
Unless otherwise stated, all chemicals were purchased
from Sigma (St. Louis, MO). The uPAR ligand, peptide
P25, sequence AESTYHHLSLGYMYTLN, and the scram-
bled peptide, S25, sequence NYHYLESSMTALYTLGH,
were synthesized by Cell Essentials (Boston, MA). The
anti-β1 antibodies, clones P5D2, 6S6, and HUTS-4 were
purchased from Chemicon (Temecula, CA). Control
mouse IgG and antibody to β-actin were obtained from
Sigma (St. Louis, MO). Secondary antibodies goat anti-
mouse and goat anti-rabbit HRP were purchased from
Bio-Rad (Hercules, CA). AlexaFluor594-labeled goat anti-
rat antibody was obtained from Molecular Probes
(Eugene, OR). 9EG7 antibody was obtained from
Pharmingen (San Diego, CA) and IST-9 antibody from
Abcam (Cambridge, England). The pCEP4 plasmid was
from Invitrogen (Carlsbad, CA) and the pCEP4 plasmid
containing the full length cDNA for human uPAR was
described previously [15] and was the gift of Dr. H. Chap-
man (University of California-San Francisco). Recom-
binant active PAI-1, active uPA, and uPAR polyclonal
antibody (399R) were from American Diagnostica
Effect of PAI-1 on P25 induced integrin activation and matrix  assembly Figure 5
Effect of PAI-1 on P25 induced integrin activation 
and matrix assembly. A – MG-63 cells monolayers, grown 
to confluency in 12-well plates, were washed and pretreated 
with different concentrations of PAI-1 for 20 minutes in the 
presence of 125I-fibronectin and then stimulated with 50 µM 
S25 or P25 for 6 hours. Cells were rinsed, scraped directly 
into 1 ml of 1% deoxycholate and the total cell bound 125I-
fibronectin was counted. B, C – MG-63 cells, grown to con-
fluency in 24-well plates, were washed, pretreated with dif-
ferent concentrations of PAI-1 for 20 minutes and incubated 
for 1 hour in DMEM containing 50 µM P25 or S25. Cells 
were then incubated for 1 hour with 100 ng/ml of either 
monoclonal antibody, HUTS-4 (B) or P5D2 (C). Cell layers 
were washed, fixed in paraformaldehyde, and incubated with 
a peroxidase conjugated secondary antibody. Bound antibody 
was detected by incubating cells with substrate, and color 
development was measured at A490 in a plate reader.Cancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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(Greenwich, CT). The non-vitronectin binding PAI-1
mutant, Q123K, was from Molecular Innovations (South-
field, MI) and the dual PAI-1R (T333→R and A335→R)
which resulted in the loss of the protease inhibitory activ-
ity of PAI-1 but did not affect its binding affinity for vit-
ronectin, was kindly provided by Dr. D. Lawrence
(Holland Lab, American Red Cross, Rockville, MD) [25].
The fragment of vitronectin 40–459, which lacks the
somatomedin B domain, was the gift of Dr R.P. Czekay
(Albany Medical College, Albany, NY), and was expressed
and purified as described previously [21].
Cell culture
The MG-63 osteosarcoma cells were grown in Dulbecco's
modified Eagle's medium (DMEM, Invitrogen), contain-
ing antibiotics (penicillin-streptomycin) and 10% fetal
bovine serum (FBS, Hyclone Laboratories, Logan, UT).
The uPAR+/+ and uPAR-/- mouse embryo fibroblasts
(MEF) cell lines have been described previously [26] and
were provided by Dr. Steve Gonias (University of Califor-
nia-San Diego). MEF were cultured in DMEM containing
10% FBS, plus antibiotics.
Isolation of the uPAR overexpressing MG-63 cell lines
Two µg of the expression vector (pCEP4) or the pCEP4-
uPAR plasmid were transfected into MG-63 cells (3 × 105)
using Lipofectamine 2000 (Invitrogen). The following
day, cells were trypsinized and transferred into two 100
mm diameter tissue culture plates. Selection (100 µg/ml
hygromycin) was started 48 hours after the transfection.
Clones were identified, isolated with cloning rings, and
expanded for testing. All transfected cell lines were
screened for uPAR expression by Western blotting. Three
clones overexpressing uPAR and three clones containing
only vector were selected for expansion and further char-
acterization.
Transient transfection of uPAR in MEF
uPAR-/- MEFs were transfected with 4 µg of pcDNA 3.1+
plasmid containing the full length cDNA for human uPAR
(pcDNA-uPAR) and 12 µl LipofectAMINETM, according to
the manufacturer instructions (Invitrogen, Carlsbad, CA).
Control cells were transfected with empty vector. Transfec-
tion efficiencies were approximately 60%, as determined
by counting fluorescent cells co-transfected with pEGFP
plasmid (Clontech). MEF were transfected for 24 hours
before matrix incorporation assay. Cells transfected with
empty vector (pLDNA3.1+) served as controls.
Purification of fibronectin and vitronectin
Human plasma fibronectin was purified from a fibronec-
tin- and fibrinogen-rich by-product of Factor VIII produc-
tion by ion exchange chromatography on DEAE-cellulose
(Amersham Biosciences) as described previously [27]. Vit-
ronectin was purified from fibronectin- and fibrinogen-
depleted human plasma by heparin-Sepharose affinity
chromatography according to the method of Yatohgo et
al. [28]. Purified plasma fibronectin (400 µg) was iodi-
nated with 1 mCi of Na125I (Perkin Elmer Life Sciences) as
described previously [29]. Iodinated fibronectin was
mixed with bovine albumin, 1 mg/ml, dialyzed against
phosphate-buffered saline, and frozen at -80°C until
used. Fibronectin (2 mg/ml) was derivatized with
PAI-1 enhancement of matrix assembly requires vitronectin Figure 6
PAI-1 enhancement of matrix assembly requires vit-
ronectin. A – MG-63 cells were plated overnight on 
fibronectin- or vitronectin-coated wells in serum-free media. 
Cells were then pretreated with PAI-1 (1µg/ml) for 20 min-
utes in the presence of 125I-fibronectin and 50 µM peptide 
was added for 6 hours. Cell layers were extracted in 1% 
DOC, and 125I-fibronectin that was incorporated into the 
detergent-insoluble matrix was recovered by centrifugation 
and measured by gamma scintillation. Control levels (S25-
treated cells) of fibronectin incorporation were set at 1 for 
each substrate. B – MG-63 cells were incubated overnight on 
wells coated with vitronectin or vitronectin fragment 40–459 
in serum-free media. Cells were then pretreated with 1 µg/
ml wild-type PAI-1 for 20 minutes in the presence of 125I-
fibronectin and 50 µM peptide was added for 6 hours. Cell 
layers were processed as described in A.Cancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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AlexaFluor488 according to the manufacturer's protocol
(Molecular Probes).
Matrix incorporation assay
MG-63 cells were seeded onto 6 well plates (2.5 × 105
cells/well) in complete medium. The following day, cul-
tures were incubated for 6 hours with 125I-fibronectin (2
µg/ml; 1 × 106 cpm/ml) in DMEM plus 0.02% BSA in the
presence of the uPAR ligand, P25, or the control peptide,
S25. For isolation of detergent insoluble matrix, cells were
rinsed in PBS, extracted in 1% deoxycholate (DOC) (in 20
mM Tris (pH 8.8) buffer containing 2 mM phenylmethyl-
sulfonyl fluoride, 2 mM EDTA, 2 mM N-ethylmaleimide,
and 2 mM iodoacetic acid). Detergent insoluble matrix
was obtained by centrifugation at 18,000 rpm for 40 min
and associated radioactivity present in the pellet meas-
ured using gamma scintillation. Preincubation with 20
nM PAI-1 (active or mutant) or uPA/PAI-1 complex and
125I-fibronectin (2 µg/ml; 1 × 106 cpm/ml) was for 20 min
in DMEM+BSA 0.02% before peptide addition. The uPA/
PAI-1 complex was prepared by reacting active two chain
uPA with an equimolar concentration of PAI-1 for 10 min
at 37°C as described previously [30]. In some experi-
ments, cells were pre-incubated with blocking antibody to
the β1 integrin prior to incubation with 125I-fibronectin.
To determine the total cell layer-associated fibronectin,
cell cultures were pretreated for 20 min with different con-
centrations of PAI-1 or uPA with 125I-fibronectin (2 µg/ml;
1 × 106 cpm/ml) in DMEM at 37 °C and then stimulated
with either P25 or S25 for 6 hours. After incubation, cells
were rinsed three times in PBS, then scraped directly into
1 ml of 1% deoxycholate and the total cell bound 125I-
fibronectin was counted. In some experiments, tissue cul-
ture wells were precoated with either 10 µg/ml fibronec-
tin, vitronectin or vitronectin fragment 40–459 in PBS for
2 hours at 37°C.
Fluorescent microscopy
To localize the P25-dependent plasma fibronectin depos-
ited into matrix with endogenous cell-derived fibronectin,
MG-63 cells were cultured in complete medium for 24
hours. Cell monolayers were incubated for an additional
16 hours in serum-free medium containing 50 µM S25 or
P25 and plasma fibronectin (2 µg/ml) derivatized with
AlexaFluor488. Cell layers were then rinsed, fixed with 3%
paraformaldehyde, permeabilized with 0.2% Triton for 5
min, and blocked for 1 hour with 1% BSA in PBS. Endog-
enous cell-derived fibronectin was visualized by incubat-
ing cells with IST-9 monoclonal antibody (2.5 µg/ml)
against cellular fibronectin. This antibody recognizes
fibronectin containing the EDA domain which is found
exclusively in cell-derived fibronectin. Cells were rinsed
and incubated with goat anti-mouse AlexaFluor594-
labeled secondary antibody. To examine the formation of
ECM contacts, coverslips were coated with fibronectin (10
µg/ml), and blocked in 1% BSA. MG-63 cells were
allowed to attach for 6 hours on fibronectin-coated cover-
slips in DMEM containing soluble AlexaFluor488-
fibronectin (20 µg/ml) and peptide (P25 or S25: 50 µM).
Cells were washed, fixed in 3% paraformaldehyde, perme-
abilized with 0.2% Triton for 5 min and blocked with 3%
milk. Cells were then incubated for 1 hour with 5 µg/ml
9EG7 antibody against active β1 integrin and bound anti-
body visualized using AlexaFluor594-conjugated goat anti-
rat antibody. Fluorophores were visualized using an
Olympus BMX-60 microscope equipped with a cooled
LCD sensi-camera. Images were acquired using Slidebook
Effect of PAI-1 mutants and uPA-PAI-1 complex on matrix  formation Figure 7
Effect of PAI-1 mutants and uPA-PAI-1 complex on 
matrix formation. A – MG-63 cells were incubated over-
night on vitronectin-coated wells in serum-free media. Cells 
were then pretreated with 1 µg/ml (20 nM) wild-type PAI-1 
or PAI-1 mutants (Q123K or PAI-1R) for 20 min in the pres-
ence of 125I-fibronectin and 50 µM peptide was added for 6 
hours. Cell layers were extracted in 1% DOC, and 125I-
fibronectin that was incorporated into the detergent-insolu-
ble matrix was recovered by centrifugation and measured by 
gamma scintillation. B – Cells were pretreated with 20 nM 
wild-type PAI-1 or uPA-PAI-1 complex for 20 min in the 
presence of 125I-fibronectin and 50 µM peptide was added for 
6 hours. Cell layers were processed as described in A.Cancer Cell International 2006, 6:8 http://www.cancerci.com/content/6/1/8
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Software (Intelligent Imaging Innovation, Inc., Denver,
CO) and processed using Adobe Photoshop.
Immunoblotting
Cell layers (3 × 105/well) were washed with PBS and lysed
with hot sample buffer [75 mM Tris-HCl (pH 6.8), 2%
SDS, 10% glycerol]. The cell lysates were boiled for 2 min
and the proteins were separated by SDS-PAGE (Bio-Rad,
Hercules, CA), transferred to nitrocellulose membranes
and blotted with the indicated antibodies.
Integrin activation assay
MG-63 cell lines were grown overnight (6 × 104 cells/well)
in 24-well plates in complete medium. The following day,
cells were treated for 2 hours in DMEM containing either
P25 or S25 and subsequently incubated for 1 hour at
37°C with either 100 ng/ml of HUTS-4 antibody, which
recognizes the activated conformation of the β1 integrin
[31-33], or 100 ng/ml P5D2, an antibody that recognizes
all forms of β1 integrin. Cells were rinsed with PBS, fixed
with 3% paraformaldehyde, blocked in 3% BSA, and incu-
bated for 1 hour with HRP-conjugated goat anti-mouse
antibody. Freshly prepared substrate (0.1 M citrate buffer,
0.5 mg/ml o-phenyl-enediamine, 1 µl/ml 30% hydrogen
peroxide pH 5.0) was added to each well, and the color
was allowed to develop. The reaction was stopped with
the addition of 2 N sulfuric acid, and the OD was meas-
ured at A490. Measurements were corrected for light scat-
tering by subtracting the OD obtained at A650. In some
experiments, cells were incubated overnight on either
fibronectin or vitronectin-coated plates in DMEM con-
taining 0.02% BSA and preincubated for 20 min with PAI-
1 (1 µg/ml) before treatment with peptides.
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